<DOC>
	<DOC>NCT00920608</DOC>
	<brief_summary>The main aim of this clinical study is to investigate whether the blood concentration of methotrexate changes when AZD9056 is co- administered together with methotrexate.</brief_summary>
	<brief_title>A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients diagnosed with rheumatoid arthritis Currently on Methotrexate treatment Provision of informed consent History of malignancy (except for treated squamous and basal cell carcinoma of the skin more than 5 years prior to entry) Patients who were taking prescription of medications listed below: Medications that are hepatic enzyme inducers and that were inhibitors of cytochrome P450, Lovastatin Leflunomide, hydroxychloroquine, cyclosporin or antitumour necrosis factor therapies within 90 days of Visit 1, or treatment with rituximab within 1 year before Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>AZD9056</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>interaction</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>